IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by IRADIMED CORP on December 12, 2023. The report details a corporate action approved by the Board of Directors regarding shareholder distributions.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data disclosed relates to dividend declarations:
- Special Cash Dividend: $0.48 per share.
- Regular Quarterly Dividend: $0.15 per share (initiated).
- Total Dividend Payable: $0.63 per share.
- Record Date: December 18, 2023.
- Payment Date: January 12, 2024.
Material Changes
The material change reported is the initiation of a regular quarterly dividend program and the declaration of a one-time special cash dividend. No prior comparable period data is provided in this specific filing for comparison.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the dividend event. The initiation of the dividend implies management's confidence in the company's cash position, though no specific liquidity analysis is included in this text.
Investor Verification Checklist
- Verify the total number of outstanding shares to calculate the aggregate cash outflow for the dividends.
- Confirm the company's current cash and cash equivalents balance in the most recent 10-Q or 10-K to assess liquidity impact.
- Review the attached press release (Exhibit 99.1) for additional context on the rationale for the special dividend.
- Check subsequent filings for confirmation of the dividend payment on January 12, 2024.